Annotation Detail

Information
Associated Genes
MGMT
Associated Variants
MGMT UNDEREXPRESSION ( ENST00000306010.8 )
MGMT UNDEREXPRESSION ( ENST00000306010.8 )
Associated Disease
glioblastoma
Source Database
CIViC Evidence
Description
In this study, patients with low MGMT expression, compared with patients with high MGMT expression, had a significantly higher response rate (55% v 7%, respectively; P = .004) and improved PFS (median, 5.5 v 1.9 months, respectively; P = .009) and OS (median, 16 v 5 months, respectively; P = .003). Among patients with MGMT data available for analysis, radiotherapy was started and completed in 91% of patients with low MGMT expression. In contrast, among patients with high MGMT expression, only 64% started radiotherapy, and 43% completed it. These results suggest that neoadjuvant chemotherapy may be feasible for inoperable glioblastoma patients expressing low levels of MGMT without compromising subsequent treatment with radiotherapy, whereas patients with high MGMT expression are less likely to respond and more likely to experience progression before or during radiotherapy.
Variant Origin
N/A
Variant Origin
N/A
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/2899
Gene URL
https://civic.genome.wustl.edu/links/genes/34
Variant URL
https://civic.genome.wustl.edu/links/variants/1255
Rating
3
Evidence Type
Predictive
Disease
Glioblastoma Multiforme
Evidence Direction
Supports
Drug
Temozolomide
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
17442989
Drugs
Drug NameSensitivitySupported
TemozolomideSensitivitytrue